Prognostic characteristics in hormone receptor-positive advanced breast cancer and characterization of abemaciclib efficacy

CDK4 & 6 inhibitors have enhanced the effectiveness of endocrine therapy (ET) in patients with advanced breast cancer (ABC). This paper presents exploratory analyses examining patient and disease characteristics that may inform in whom and when abemaciclib should be initiated. MONARCH 2 and 3 en...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:NPJ Breast Cancer
Egile Nagusiak: Di Leo, Angelo, O’Shaughnessy, Joyce, Sledge, George W., Martin, Miguel, Lin, Yong, Frenzel, Martin, Hardebeck, Molly C., Smith, Ian C., Llombart-Cussac, Antonio, Goetz, Matthew P., Johnston, Stephen
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Nature Publishing Group UK 2018
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC6299082/
https://ncbi.nlm.nih.gov/pubmed/30588487
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41523-018-0094-2
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak